Media Articles Related to Trileptal (Oxcarbazepine)
New indication for VIMPAT®: anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures
Source: Epilepsy News From Medical News Today [2014.09.03]
UCB has announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for VIMPAT® (lacosamide) C-V as monotherapy in the treatment of...
Potential treatments for absence seizures
Source: Epilepsy News From Medical News Today [2014.08.25]
Absence seizures are believed to be elicited by T-type calcium channels in the thalamic reticular nucleus of the brain that regulate influxes of calcium.
Two Drugs Work Equally Well for Epileptic Seizures in Kids: Study
Source: MedicineNet lorazepam Specialty [2014.04.23]
Title: Two Drugs Work Equally Well for Epileptic Seizures in Kids: Study
Category: Health News
Created: 4/22/2014 4:36:00 PM
Last Editorial Review: 4/23/2014 12:00:00 AM
Source: MedicineNet Roseola Specialty [2014.01.15]
Title: Febrile Seizures
Category: Diseases and Conditions
Created: 5/9/2008 12:00:00 AM
Last Editorial Review: 1/15/2014 12:00:00 AM
Most Vaccination-Onset Epilepsy Has Genetic, Structural Cause
Source: Medscape Infectious Diseases Headlines [2014.09.24]
A new study shows that most seizures beginning after vaccination have an underlying genetic or structural cause, which should increase faith in vaccine safety, researchers say.
Medscape Medical News
Published Studies Related to Trileptal (Oxcarbazepine)
Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared with a single oral dose of oxcarbazepine. [2011.06]
Oxcarbazepine (OXC) is an antiepileptic drug...
Effect of eslicarbazepine acetate and oxcarbazepine on cognition and psychomotor function in healthy volunteers. [2010.08]
The results of two single-blind studies conducted to evaluate the cognitive and psychomotor effects of eslicarbazepine acetate and oxcarbazepine following single and repeated administration in healthy volunteers are reported...
[Efficacy and safety of the monotherapy with trileptal (oxcarbazepine) in children and adolescents.] 
A prospective non-randomized non-controlled multicenter trial has been conducted. The trial included 254 children, aged from 11 months to 18 years (mean age 9,3+/-4,5 years), with predominantly focal forms of epilepsy treated with trileptal (oxcarbazepine)... In conclusion, trileptal as the monotherapy is effective and well-tolerated in the treatment of focal epilepsies in the age groups studied.
Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. [2009.04]
CONCLUSION: Oxcarbazepine demonstrated comparable efficacy to divalproex sodium in the management of acute mania. Also the overall adverse event profile was found to be superior for oxcarbazepine.
Effect of Oxcarbazepine in the Treatment of Agitation and Aggression in Severe Dementia. [2009.02.02]
Background/Aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer's disease, vascular dementia or both. Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry...
Clinical Trials Related to Trileptal (Oxcarbazepine)
Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain [Recruiting]
The purpose of this trial is to determine if the effect of oxcarbazepine on chronic
peripheral nerve pain depends on the supposed mechanism of the pain, ie. if oxcarbazepine
mainly relieve pain in patients with irritable nerves.
Levetiracetam Versus Oxcarbazepine as Monotherapy to Evaluate Efficacy and Safety in Subject With Partial Epilepsy [Recruiting]
To evaluate the long term effectiveness of Levetiracetam (LEV) monotherapy on Treatment
Failure Rate in subjects with newly diagnosed partial onset seizures with or without
secondary generalized seizures, compared to Oxcarbazepine (OXC) monotherapy over 50 weeks
from the first dose
Safety and Efficacy of Oxcarbazepine Monotherapy in Adults With Partial Seizures [Completed]
This study is aimed to evaluate the efficacy, safety and tolerability of oxcarbazepine
monotherapy in adults with partial seizures.
Induction of Drug Metabolism: In Vivo Comparison of Carbamazepine and Oxcarbazepine. [Active, not recruiting]
This is a study of the possible effect of two antiepileptic drug on enzymes in the liver that
metabolizes a number of drugs. It is a well know fact that carbamazepine induces some of
these enzymes and this may reduce the effect of concomitantly administered drugs. Clinical
observations suggest that oxcarbazepine does not induce these enzymes to the same degree.
This study directly compares the ability of these two drugs to induce the cytochrome P450 3A4
enzyme, in healthy volunteers using a well defined biomarker reaction of a specific enzyme
It is the hypothesis that oxcarbazepine induces CYP3A4 to a lesser degree than
Oxcarbazepine as an Adjunct of Antipsychotic Therapy in Acute Schizophrenia [Recruiting]
Over recent years an approach with the adjunctive administration of various anticonvulsant
drugs has been discussed and a limited number of open and controlled studies were performed
for carbamazepine, valproic acid, and lamotrigine. While the latter shows promising effects
in the long run it has some handling difficulties in the acute treatment of acute psychotic
exacerbations. Valproic acid has shown inconsistent effects in schizophrenia with no
significant effects in a recent controlled study. Although still controversially discussed,
carbamazepine was found to offer beneficial effects in the treatment of schizophrenia.
Nonetheless, data on these effects are limited by small sample sizes or poor design of most
of the respective studies. Furthermore, the complex pharmaco-logical interactions of new
atypical neuroleptics with carbamazepine underline the necessity of alternative strategies in
adjuvant treatment of schizophrenia as well as in combined treatment of bipolar disorders
with mood stabilizers and neuroleptics.
Oxcarbazepine (OXC) is a new anticonvulsant drug that acts as a pro-drug for the
10-monohydroxy metabo-lite (MHD), an active metabolite also of carbamazepine that is
suggested to be responsible for most of its therapeutic actions. Therefore, the
pharmacological action of OXC is very well comparable to carbamazepine whilst there are fewer
unwanted side effects of OXC regarding eg. skinrush, and effects on blood compounds or
The effects of OXC on cytochrome CYP3A4 and CYP3A5 are moderate and UDPGT is only slightly
affected by OXC, which leads to less interaction with other compounds on a pharmacokinetical
In psychiatry, the few studies published until now report positive effects of OXC in bipolar
disorders. With regards to our own clinical observations, OXC has shown potential beneficial
effects as an adjunct in the treatment of schizophrenia as well that require further
evaluation in a controlled study design.
Reports of Suspected Trileptal (Oxcarbazepine) Side Effects
Feeling Abnormal (27),
Pyrexia (21), more >>